VIB VERMOEGEN AG (VIH1.DE) Stock Fundamental Analysis
Europe - FRA:VIH1 - DE000A2YPDD0 - Common Stock
8.8 EUR
-0.12 (-1.35%)
VIH1 gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 67 industry peers in the Real Estate Management & Development industry. VIH1 has only an average score on both its financial health and profitability. VIH1 scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
In the past year VIH1 was profitable.
VIH1 had a positive operating cash flow in the past year.
Each year in the past 5 years VIH1 has been profitable.
In the past 5 years VIH1 always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 1.90%, VIH1 is doing good in the industry, outperforming 64.18% of the companies in the same industry.
VIH1's Return On Equity of 4.11% is fine compared to the rest of the industry. VIH1 outperforms 61.19% of its industry peers.
The Return On Invested Capital of VIH1 (3.52%) is better than 71.64% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for VIH1 is in line with the industry average of 3.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.9% | ||
| ROE | 4.11% | ||
| ROIC | 3.52% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
1.3 Margins
VIH1 has a better Profit Margin (34.63%) than 74.63% of its industry peers.
VIH1's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 70.15%, VIH1 belongs to the best of the industry, outperforming 89.55% of the companies in the same industry.
VIH1's Operating Margin has declined in the last couple of years.
VIH1 has a Gross Margin of 78.88%. This is in the better half of the industry: VIH1 outperforms 67.16% of its industry peers.
In the last couple of years the Gross Margin of VIH1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% |
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
2. Health
2.1 Basic Checks
VIH1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for VIH1 remains at a similar level compared to 1 year ago.
Compared to 5 years ago, VIH1 has more shares outstanding
Compared to 1 year ago, VIH1 has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.81, we must say that VIH1 is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VIH1 (0.81) is comparable to the rest of the industry.
VIH1 has a debt to FCF ratio of 9.58. This is a negative value and a sign of low solvency as VIH1 would need 9.58 years to pay back of all of its debts.
VIH1 has a better Debt to FCF ratio (9.58) than 74.63% of its industry peers.
VIH1 has a Debt/Equity ratio of 0.92. This is a neutral value indicating VIH1 is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.92, VIH1 is in line with its industry, outperforming 44.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | 9.58 | ||
| Altman-Z | 0.81 |
ROIC/WACC0.79
WACC4.44%
2.3 Liquidity
A Current Ratio of 1.77 indicates that VIH1 should not have too much problems paying its short term obligations.
The Current ratio of VIH1 (1.77) is comparable to the rest of the industry.
A Quick Ratio of 1.77 indicates that VIH1 should not have too much problems paying its short term obligations.
The Quick ratio of VIH1 (1.77) is better than 71.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.77 |
3. Growth
3.1 Past
The earnings per share for VIH1 have decreased strongly by -72.11% in the last year.
VIH1 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.74% yearly.
Looking at the last year, VIH1 shows a small growth in Revenue. The Revenue has grown by 4.50% in the last year.
Measured over the past years, VIH1 shows a small growth in Revenue. The Revenue has been growing by 2.78% on average per year.
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%-79.27%
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%22.19%
3.2 Future
The Earnings Per Share is expected to grow by 11.54% on average over the next years. This is quite good.
The Revenue is expected to grow by 10.81% on average over the next years. This is quite good.
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VIH1 is valuated reasonably with a Price/Earnings ratio of 8.07.
Compared to the rest of the industry, the Price/Earnings ratio of VIH1 indicates a rather cheap valuation: VIH1 is cheaper than 86.57% of the companies listed in the same industry.
VIH1's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.43.
VIH1 is valuated cheaply with a Price/Forward Earnings ratio of 4.54.
Based on the Price/Forward Earnings ratio, VIH1 is valued cheaper than 95.52% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.87, VIH1 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.07 | ||
| Fwd PE | 4.54 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VIH1 indicates a rather cheap valuation: VIH1 is cheaper than 95.52% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, VIH1 is valued cheaply inside the industry as 89.55% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.2 | ||
| EV/EBITDA | 4.86 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of VIH1 may justify a higher PE ratio.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a yearly dividend of 0.45%, VIH1 is not a good candidate for dividend investing.
VIH1's Dividend Yield is comparable with the industry average which is at 7.97.
With a Dividend Yield of 0.45, VIH1 pays less dividend than the S&P500 average, which is at 2.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.45% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y11.54%
EPS Next 3YN/A
FRA:VIH1 (9/11/2025, 7:00:00 PM)
8.8
-0.12 (-1.35%)
Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)
Earnings (Next)
Inst Owners0.94%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap290.84M
Analysts82.86
Price Target11.73 (33.3%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.45% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.07 | ||
| Fwd PE | 4.54 | ||
| P/S | 2.79 | ||
| P/FCF | 3.2 | ||
| P/OCF | 3.19 | ||
| P/B | 0.33 | ||
| P/tB | 0.34 | ||
| EV/EBITDA | 4.86 |
EPS(TTM)1.09
EY12.39%
EPS(NY)1.94
Fwd EY22.02%
FCF(TTM)2.75
FCFY31.27%
OCF(TTM)2.76
OCFY31.35%
SpS3.16
BVpS26.58
TBVpS25.59
PEG (NY)0.77
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.9% | ||
| ROE | 4.11% | ||
| ROCE | 4.09% | ||
| ROIC | 3.52% | ||
| ROICexc | 3.79% | ||
| ROICexgc | 3.87% | ||
| OM | 70.15% | ||
| PM (TTM) | 34.63% | ||
| GM | 78.88% | ||
| FCFM | 87.15% |
ROA(3y)4.03%
ROA(5y)3.75%
ROE(3y)8.99%
ROE(5y)8.64%
ROIC(3y)4.05%
ROIC(5y)4.34%
ROICexc(3y)4.4%
ROICexc(5y)4.63%
ROICexgc(3y)4.52%
ROICexgc(5y)4.7%
ROCE(3y)4.69%
ROCE(5y)5.03%
ROICexcg growth 3Y-10.75%
ROICexcg growth 5Y-3.98%
ROICexc growth 3Y-11.34%
ROICexc growth 5Y-4.36%
OM growth 3Y-3.76%
OM growth 5Y-2.01%
PM growth 3Y5.97%
PM growth 5Y-12.98%
GM growth 3Y-2.37%
GM growth 5Y-0.86%
F-Score5
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | 9.58 | ||
| Debt/EBITDA | 3.78 | ||
| Cap/Depr | 0.16% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 2.12 | ||
| Cash Conversion | 42.81% | ||
| Profit Quality | 251.67% | ||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.77 | ||
| Altman-Z | 0.81 |
F-Score5
WACC4.44%
ROIC/WACC0.79
Cap/Depr(3y)0.86%
Cap/Depr(5y)88.75%
Cap/Sales(3y)0.31%
Cap/Sales(5y)0.52%
Profit Quality(3y)144.88%
Profit Quality(5y)156.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-72.11%
EPS 3Y0.35%
EPS 5Y-13.74%
EPS Q2Q%-79.27%
EPS Next Y10.47%
EPS Next 2Y11.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.5%
Revenue growth 3Y0.51%
Revenue growth 5Y2.78%
Sales Q2Q%22.19%
Revenue Next Year13.92%
Revenue Next 2Y10.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.54%
EBIT growth 3Y-3.27%
EBIT growth 5Y0.72%
EBIT Next Year69.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.92%
FCF growth 3Y6.73%
FCF growth 5YN/A
OCF growth 1Y22%
OCF growth 3Y6.76%
OCF growth 5Y5.7%